Wortmannin is an inhibitor of PI3 kinase, and sensitizes cells to radiation. But clinical development of the compound has mostly been a bust. Oncothyreon Inc.'s wortmannin derivative PX-866 is in several Phase II monotherapy and combination trials for various cancers, but multiple other derivatives as well as wortmannin itself have failed because they have been poorly soluble, unstable and toxic.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter